|
|
 |
|
Viewing report
|
|
|
|
Competitor Analysis: MEK Inhibitors
La Merie Publishing, June 2009, Pages: 17
The present Competitive Intelligence Report about MEK Inhibitors provides a competitor evaluation in the field of synthetic molecules targeting MEK pathway for treatment of cancer as of June 2009.
The mitogen activated protein kinases (MAPKs) are conserved proteins that regulate cell growth, division and death. Although activated in the cytosol, the MAPKs translocate to the nucleus upon activation and phosphorylate a large number of nuclear proteins. Investigating how Ras transmits extracellular growth signals, the MAPK pathway has emerged as the crucial route between membrane-bound Ras and the nucleus. The MAPK pathway represents a cascade of phosphorylation events including three pivotal kinases, namely Raf, MEK (MAP kinase kinase), and ERK (MAP kinase).
The report includes a compilation of current active projects in research and development of synthetic molecules targeting the Mitogen-activated ERK kinase (MEK) pathway. In addition, the report lists company-specific R&D pipelines of MEK targeting molecules. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Customers who bought this item also bought
Competitor Analysis: Raf Inhibitors
Competitor Analysis: Ras-Raf-MEK-ERK Inhibitors
Competitor Analysis - p38 MAPK Inhibitors 2010
Oncology Pipeline Database
Analytical Tool - Protein Kinase Inhibitors in Oncology
Competitor Analysis: Aurora Kinase Inhibitors
Competitor Analysis: Novel Mitotic Kinase Inhibitors
Competitor Analysis: Novel Mitotic Kinase Inhibitors
B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2012
Competitor Analysis - PI3K-AKT-mTOR Inhibitors
|
|
|
|
